MA-INRUPT
23.7.2024 14:01:30 CEST | Business Wire | Press release
Today, Inrupt, the leading provider of enterprise-grade software for the web, announced the launch of its Data Wallet. Enterprises and governments use the technology to give their customers and citizens digital wallets for their data, creating a foundation for innovative, intuitive and impactful digital experiences.
Over 60% of the world’s population is expected to use digital wallets regularly by 2026, and over half of consumers report interest in using them for a broader range of purposes. But the existing market has focused largely on financial transactions and is dominated by a handful of Big Tech vendors.
Inrupt’s Data Wallet technology represents the next evolution of standard, interoperable digital wallets. Unlike alternatives, Inrupt’s solution accepts a wide variety of data and makes it easy for individuals to consent to access their data. The Data Wallet opens new opportunities for organizations as the web shifts toward a user-centric approach to how personal data is managed, shared, and used.
“Browsers shaped the Web 1.0 era, and Web 2.0 was all about apps. But Web 3.0 is all about empowered individuals and personal data. The Data Wallet becomes a fundamental tool for users,” said Sir Tim Berners-Lee, inventor of the World Wide Web and CTO and co-founder of Inrupt. “By making this key piece of technology available, Inrupt is ensuring that the opportunities and benefits of secure personal Data Wallets are open for everyone.”
The explosion of new use cases for digital wallets, and the types of data they store, represents a major shift in consumer behavior. For organizations, it’s a chance to improve and grow relationships with customers and citizens. In order to capitalize on the opportunity that digital wallets represent, organizations can rely on Inrupt’s standards-based approach to quickly build, integrate, and test new wallet offerings — or enhance their current wallet applications — all while giving users confidence that they have transparency and control of their most important personal data.
"Digital wallets are fast becoming the most compelling way to serve your customers and citizens. Organizations need to assess their wallet strategy,” said John Bruce, CEO and co-founder of Inrupt. “We built our Data Wallet to be easy to use — both for organizations and their users. It’s a direct channel of communication for valuable, relevant data."
Until now, digital wallets have been siloed “point solutions,” requiring different wallets for different purposes. But global initiatives like the EU’s Digital Identity Wallet are already showing organizations the benefits of standardization and interoperability. With a multi-purpose Data Wallet, organizations can access and verify government-issued credentials like passports, educational certificates and entitlement benefits, even across state and national borders.
Inrupt’s Data Wallet solution is built on the company’s Enterprise Solid Server (ESS), which is powering mission-critical deployments of the Solid protocol, the open web standard, around the world. Because of this foundation, it’s easy to reuse the personal data stored in the Data Wallet in other apps, services and AI systems. Consent for access is always coupled with each piece of data, so users can trust their data is used the way they want, and organizations can be confident they’re in compliance with any relevant data regulations.
“Digital wallets aren’t just for payments anymore. With the Data Wallet adding identity and consent capabilities, they are quickly becoming the gateway to our digital lives and will soon be the main interface used for data sharing, management and collaboration,” said Osmar Olivo, VP of Product at Inrupt. “By moving towards standardization with an underlying infrastructure like Solid, this wealth of information can be used flexibly, securely, and as intended across any sector in order to deliver better services, products, or experiences.”
“It’s clear that digital wallets are the new basecamp for a huge variety of digital activities. What’s not yet determined is whether this change will reinforce the power of the few, or open new advantages for the many,” said John Bruce. “Inrupt will always build technology intended to benefit the many, and our Data Wallet is the most important example yet.”
Click here to learn more about Inrupt’s Data Wallet features and capabilities or request a demo.
About Inrupt
Inrupt is a leading provider of enterprise-grade software for the web. Enterprises and governments rely on our technology to build new, innovative products and services — all based on a platform of interoperable data and consent from customers and citizens.
Co-founded by World Wide Web inventor Sir Tim Berners-Lee, Inrupt scales and secures the Solid protocol, the open web standard. The company’s Enterprise Solid Server (ESS) stores and protects personal data for enterprises and governments. On this foundation they can quickly build user Data Wallets and applications that take advantage of this new source of authentic data directly from customers and citizens.
Inrupt’s global presence spans the US, UK, Europe and APAC. The company works with organizations across various sectors, including Financial Services, Retail, Government, Healthcare, and Media/Telco. Founded in 2017, Inrupt’s mission is to ensure a better, safer future of data, AI, and the web.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723678725/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
